Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY

Launched by ISTITUTO AUXOLOGICO ITALIANO · Mar 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying changes in the genes of papillary thyroid cancer (PTC) tumors to better understand how these changes affect treatment outcomes and patient health. Researchers have found that many PTC tumors have specific gene mutations that can influence how the disease behaves and how well different treatments may work. By analyzing tumor samples using a special technology called Mass ARRAY, the study aims to identify these mutations in a large number of patients, which can help predict their prognosis and tailor personalized therapies.

To be eligible for this trial, patients must have been diagnosed with papillary thyroid cancer and be able to provide a sample of their tumor tissue for testing. Importantly, patients need to give their consent to participate. If you choose to join the study, you can expect that your tumor sample will be analyzed for specific genetic changes, and the results may help inform future treatments for you and others with similar conditions. This trial is currently looking for participants, so it could be a valuable opportunity to contribute to important research in the field.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients with papillary thyroid cancer
• • patients whose tumor tissue can be recovered for genetic analysis
• Exclusion Criteria:
• • patients who did not give consent
• • patients lost to follow-up
• • tumor samples not suitable for genetic analysis